<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32125520</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>267</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Patient reported outcome measures (PROMs) in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1754</StartPage><EndPage>1759</EndPage><MedlinePgn>1754-1759</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-020-09774-8</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Patient reported outcome measures (PROMs) can provide researchers with a direct view of patients' experiences. They are becoming increasingly important tools for evaluating clinical care and research outcomes. There has been little data on the application of PROMs to amyotrophic lateral sclerosis (ALS) care. The objective of this study was to examine the feasibility of PROM collection in an academic ALS clinic and to measure correlations between PROMs and standard ALS clinical outcome measures.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PROMs were gathered from tablet-based surveys offered to adult patients in the waiting room, prior to ALS outpatient clinic visits. They included a demographic section and two validated surveys: the patient reported outcome measurement information system (PROMIS-10), which generates physical health and mental health subscores, and the quality of life in neurological disorders-fatigue subscale (NeuroQoL-fatigue). The ALS functional rating scale-revised (ALSFRS-R) and other ALS measures were collected by clinic staff as part of routine clinical care.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">PROMIS-10 physical and mental health scores correlated positively with the ALSFRS-R score (physical: R&#x2009;=&#x2009;0.85, p&#x2009;&lt;&#x2009;0.001; mental: R&#x2009;=&#x2009;0.58, p&#x2009;=&#x2009;0.02). NeuroQoL-fatigue scores were inversely correlated with the ALSFRS-R scores-higher fatigue correlated with lower function (R&#x2009;=&#x2009;-&#xa0;0.72, p&#x2009;=&#x2009;0.004).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Collection of PROMs is feasible in the context of routine ALS care. PROM scores are highly correlated with validated ALS outcome measures.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>De Marchi</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0197-1880</Identifier><AffiliationInfo><Affiliation>Healey Center for ALS, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge St, Suite 600, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Healey Center for ALS, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge St, Suite 600, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Biostatistics Center, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Healey Center for ALS, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge St, Suite 600, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellrodt</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Healey Center for ALS, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge St, Suite 600, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scalia</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Healey Center for ALS, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge St, Suite 600, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Healey Center for ALS, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge St, Suite 600, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Ton</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Healey Center for ALS, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge St, Suite 600, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark Sisodia</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Massachusetts General Physicians Organization, Harvard Medical School, MGH Partners Healthcare, Somerville, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwamm</LastName><ForeName>Lee H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moura</LastName><ForeName>Lidia M V R</ForeName><Initials>LMVR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Healey Center for ALS, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge St, Suite 600, Boston, MA, USA. SPAGANONI@mgh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA. SPAGANONI@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000554" MajorTopicYN="N">Ambulatory Care Facilities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034201" MajorTopicYN="N">Computers, Handheld</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="Y">Patient Reported Outcome Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058996" MajorTopicYN="N">Quality Improvement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Measures</Keyword><Keyword MajorTopicYN="N">Neurology</Keyword><Keyword MajorTopicYN="N">Outcome</Keyword><Keyword MajorTopicYN="N">PROMs</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32125520</ArticleId><ArticleId IdType="doi">10.1007/s00415-020-09774-8</ArticleId><ArticleId IdType="pii">10.1007/s00415-020-09774-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cella D, Yount S, Rothrock N et al (2007) The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 45:S3&#x2013;S11</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.mlr.0000258615.42478.55</ArticleId></ArticleIdList></Reference><Reference><Citation>Cella D, Riley W, Stone A et al (2010) The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005&#x2013;2008. J Clin Epidemiol 63:1179&#x2013;1194</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2010.04.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura LM, Schwamm E, Moura Junior V et al (2016) Feasibility of the collection of patient-reported outcomes in an ambulatory neurology clinic. Neurology 87:2435&#x2013;2442</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003409</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaffler N, Schonberg P, Stephan J, Stellmann JP, Gold SM, Heesen C (2013) Comparison of patient-reported outcome measures in multiple sclerosis. Acta Neurol Scand 128:114&#x2013;121</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12083</ArticleId></ArticleIdList></Reference><Reference><Citation>Heatwole C, Bode R, Johnson N et al (2012) Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology 79:348&#x2013;357</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318260cbe6</ArticleId></ArticleIdList></Reference><Reference><Citation>Heatwole C, Johnson N, Bode R et al (2015) Patient-reported impact of symptoms in myotonic dystrophy type 2 (PRISM-2). Neurology 85:2136&#x2013;2146</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002225</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobi H, du Montcel ST, Bauer P et al (2018) Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias. J Neurol 265:2040&#x2013;2051</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8954-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongiovi P, Dilek N, Garland C et al (2018) Patient reported impact of symptoms in spinal muscular atrophy (PRISM-SMA). Neurology 91:e1206&#x2013;e1214</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006241</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulla S, Vielhaber S, Korner S et al (2013) Validation of the German version of the extended ALS functional rating scale as a patient-reported outcome measure. J Neurol 260:2242&#x2013;2255</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-013-6955-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RA, Macklin EA, Myers KJ et al (2018) Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale). Eur J Neurol 25:907</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13638</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens HE, Joyce NC, Oskarsson B (2017) National study of muscle cramps in ALS in the USA. Amyotroph Lateral Scler Frontotemporal Degener 18:32&#x2013;36</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1245755</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt S, Petri S, Dengler R, Heinze HJ, Vielhaber S (2018) Dyspnea in amyotrophic lateral sclerosis (ALS): Rasch-based development and validation of a patient-reported outcome (DALS-15). J Pain Symptom Manage 56:736&#x2013;745</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpainsymman.2018.08.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169:13&#x2013;21</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Miller RG, Moore DH (2004) Alsfrs-R. Amyotroph Lateral Scler Other Motor Neuron Disord 5(Suppl 1):90&#x2013;93</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17434470410019906</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Meng L, Kulke SF et al (2018) Association between decline in slow vital capacity and respiratory insufficiency, use of assisted ventilation, tracheostomy, or death in patients with amyotrophic lateral sclerosis. JAMA Neurol 75:58&#x2013;64</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.3339</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Liu D, Leitner ML et al (2016) Quantitative strength testing in ALS clinical trials. Neurology 87:617&#x2013;624</Citation><ArticleIdList><ArticleId IdType="pubmed">27385750</ArticleId><ArticleId IdType="pmc">4977369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O et al (2015) A revision of the El Escorial criteria&#x2014;2015. Amyotroph Lateral Scler Frontotemporal Degener 16(5&#x2013;6):291&#x2013;292</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1049183</ArticleId></ArticleIdList></Reference><Reference><Citation>Broderick JE, DeWitt EM, Rothrock N, Crane PK, Forrest CB (2013) Advances in patient-reported outcomes: the NIH PROMIS((R)) measures. EGEMS (Wash DC) 1:1015</Citation></Reference><Reference><Citation>Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D (2009) Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res 18:873&#x2013;880</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-009-9496-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Cella D, Lai JS, Nowinski CJ et al (2012) Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology 78:1860&#x2013;1867</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318258f744</ArticleId></ArticleIdList></Reference><Reference><Citation>Gershon RC, Lai JS, Bode R et al (2012) Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res 21:475&#x2013;486</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-011-9958-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B (1983) Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 127:725&#x2013;734</Citation><ArticleIdList><ArticleId IdType="pubmed">6859656</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons C, Pagnini F, Friede T, Young CA (2018) Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 1:CD011005</Citation><ArticleIdList><ArticleId IdType="pubmed">29293261</ArticleId></ArticleIdList></Reference><Reference><Citation>Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121&#x2013;1123</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1989.00520460115022</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Cudkowicz M, Berry JD (2014) Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig (Lond) 4:605&#x2013;618</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/cli.14.52</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly L, Jenkinson C, Morley D (2015) Outcome measurement in neurodegenerative disease: attributes, applications &amp; interpretation. Neurodegener Dis Manag 5:305&#x2013;316</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nmt.15.25</ArticleId></ArticleIdList></Reference><Reference><Citation>Dirven L, Taphoorn MJ, Reijneveld JC et al (2014) The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: a systematic review. Eur J Cancer 50:2432&#x2013;2448</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2014.06.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson AC, Delavaran H, Iwarsson S, Stahl A, Norrving B, Lindgren A (2014) Functional status and patient-reported outcome 10 years after stroke: the Lund Stroke Register. Stroke 45:1784&#x2013;1790</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.114.005164</ArticleId></ArticleIdList></Reference><Reference><Citation>Markman JD, Gewandter JS, Frazer ME et al (2015) Evaluation of outcome measures for neurogenic claudication: a patient-centered approach. Neurology 85:1250&#x2013;1256</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002000</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>